CA-PERSONALIS
17.12.2020 15:09:10 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary, machine learning-based tool for the comprehensive identification and characterization of cancer neoantigens. Integrated into the Personalis® NeXT Platform™, SHERPA enables the development of new neoantigen-based diagnostic biomarkers, such as the company’s proprietary Neoantigen Presentation Score (NEOPS™), and novel personalized therapies.
Data presented at the SITC Annual Meeting in November 2020 showed SHERPA outperforming commonly used neoantigen binding prediction tools in clinical tumor samples. “With more accurate neoantigen presentation prediction, we are looking to enable a new generation of precision oncology applications,” said Richard Chen, MD, Personalis CSO. “Trained on a proprietary immunopeptidomics dataset derived from engineered cell lines, SHERPA improves neoantigen presentation prediction compared to other in silico methods. With this advancement, SHERPA can enable more predictive biomarkers for cancer therapy as well as facilitate the development of neoantigen-targeting, personalized cancer therapies. Our recently-launched NEOPS is one example of a SHERPA-derived composite biomarker that has shown promise in predicting immunotherapy response in cancer patients.”
While most conventional in silico methods generally only assess the potential MHC-binding affinity and stability of identified peptides, SHERPA goes a step further by incorporating features relating to the antigen processing machinery and RNA abundance to generate a presentation rank for each detected peptide. This serves to determine the relative likelihood of a given neoantigen being presented and undergoing immunosurveillance.
This launch represents the broader commercial release of SHERPA, which is currently being leveraged by Personalis’ preferred partner, Sarepta Therapeutics, to characterize immune response to precision genetic therapeutics in patients with rare diseases, demonstrating the applicability of this machine learning tool in disease areas beyond cancer.
About Personalis, Inc.
Personalis, Inc. is a leader in cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of SHERPA, NEOPS or the Personalis NeXT Platform, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005355/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GigaDevice Extends European Reach with SEMITRON Partnership for DACH region12.2.2026 10:52:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has entered into a distribution agreement with SEMITRON, a leading electronic component distributor that specializes with a focus on the DACH region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203746978/en/ Under the terms of the deal, SEMITRON is set to supply both GigaDevice's leading Flash, MCU, power and sensor lines in conjunction with field application engineering support to customers in the industrial, automotive and communication technology sectors. In particular, SEMITRON offers professional test house services, technical know-how and local on-the-ground expertise and support. The partnership further extends GigaDevice's reach into this major European market, with on the ground support in Germany, Austria, Switzerland. Jürgen Rohland, Managing Director of SEMITRON W. Röck Gmb
Samsung Ships Industry-First Commercial HBM4 With Ultimate Performance for AI Computing12.2.2026 10:48:00 CET | Press release
Mass production commences for HBM4 with consistent transfer speed of 11.7Gbps, capable of up to 13GbpsLeading-edge DRAM with 4nm logic base die maximizes performance, reliability and energy efficiency for next-generation datacentersSecure process technology and supply capabilities strengthen Samsung’s HBM roadmap beyond HBM4 Samsung Electronics Co., Ltd., a global leader in advanced memory technology, today announced that it has begun mass production of its industry-leading HBM4 and has shipped commercial products to customers. This achievement marks a first in the industry, securing an early leadership position in the HBM4 market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212674509/en/ Samsung Ships Industry-First Commercial HBM4 With Ultimate Performance for AI Computing By proactively leveraging its most advanced 6th-generation 10 nanometer (nm)-class DRAM process (1c), the company achieved stable yields and indus
Sisvel Website Now Available in Chinese and Japanese12.2.2026 10:30:00 CET | Press release
Chinese and Japanese language versions of the Sisvel corporate website are now live, delivering an enhanced experience for users in two of the world’s key technology markets. The move also reflects the growing role of Asia-based innovators and implementers in Sisvel licensing programmes. The localised sites will enable more SEP licensing stakeholders to access patent pool information and programme details in their native languages. All versions of the website will be updated continuously to carry the full range of Sisvel news and insights. “Sisvel is deeply embedded in the markets where we operate,” says Sisvel Executive Head of Brand Giulia Dini. “Our expanded online presence in Asia, which also includes the recent launch of an official WeChat channel, aligns with our growing physical footprint in the region. We look forward to driving the global conversation on patent licensing and innovation.” In 2025, Sisvel appointed senior executives to run its operations in Japan and China. The
In the age of AI agents, Splio makes prediction the foundation of CRM and launches its AI-first CRM12.2.2026 09:30:00 CET | Press release
Splio is setting prediction as the new CRM standard and the future interface for AI agentsThe company has evolved Tinyclues AI, initially focused on predictive AI, into an AI enhanced with generative and agentic capabilities, now integrated at the core of its platform Commercial launch of the AI-first CRM powered by Tinyclues AI Launch of the Ask my CRM agent, an intelligent copilot to speed up decision-making and CRM execution based on customer data The company is positioning itself as an AI-first company, already generating 30% of its revenue from AI and aiming for 50% in 2027 Splio announces the launch of its AI-first CRM powered by Tinyclues AI. Now integrated at the core of the platform, predictive AI helps brands orchestrate and personalize their communications at scale across every channel (email, SMS, RCS, WhatsApp...). Splio also unveils "Ask My CRM," its new AI agent designed as an intelligent marketing copilot that, plugged into each brand's customer data, makes customer kno
Stafford Capital Partners Announces New Renewable Energy Investment Strategy with Dedicated Team12.2.2026 09:00:00 CET | Press release
Stafford Capital Partners integrates dedicated renewables team tostrengthen the firm’s strategic infrastructure investing capabilities with a focus on energy transition opportunities. Stafford Capital Partners (“Stafford”), a leading international private markets investment and advisory firm, today announced the launch of a new strategy focused on the renewable energy sector. This initiative leverages the ongoing transformation and rapid growth within the renewables market, targeting the revamping and repowering of existing renewable assets to deliver compelling risk-adjusted returns while accelerating the transition to a low-carbon economy. This new strategic initiative further strengthens Stafford’s position in the global infrastructure investment market, providing institutions with access to a pioneering investment approach to renewable investing. This mirrors the differentiated approach Stafford has taken in developing its secondary market strategies across its real assets platform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom